A B S T R A C T Dihydrotestosterone binding was measured in cultured fibroblasts from 14 control subjects and from 12 patients with five different types of hereditary male pseudohermaphroditism. Two assays of binding were used-an intact monolayer assay and density gradient centrifugation of cell extracts. In the intact monolayer assay of normal cells the uptake of [3H]dihydrotestosterone consisted of two components. The first was a high affinity component that exhibited saturation at approximately 1 nM dihydrotestosterone. The second was a low affinity component that was not saturable with concentrations of steroid up to 5 nM. Twice the number of high affinity binding sites were present in fibroblasts grown from genital skin (foreskin, labia majora, and scrotum) as from nongenital sites (37 vs. 14 fmol/mg protein). In the density gradient assay in 5-20% sucrose, the major peak of dihydrotestosterone binding was in the 8S region in low molarity buffer and in the 4S region in 0.5 M KC1.
High affinity binding was normal in cells from two patients with familial incomplete male pseudohermaphroditism, type 2, an autosomal recessive defect in which dihydrotestosterone formation is deficient, and in cells from a patient with male pseudohermaphroditism due to This work was presented in part at the Midwestern Section of the American Federation for Clinical Research in Chicago, Ill., on 6 November 1975 , and has been published in abstract form (Clin. Res. 23: 478A, 1975 ).
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17P-hydroxysteroid dehydrogenase deficiency, an autosomal recessive defect of testosterone synthesis. High affinity binding was low by both methods in fibroblasts from five patients with complete testicular feminization. Furthermore, binding by both methods was also low in cells from three subjects with familial incomplete male pseudohermaphroditism, type 1, a presumed X-linked recessive disorder of androgen resistance, and in fibroblasts grown from a subject with the incomplete form of testicular feminization.
The finding that dihydrotestosterone binding is abnormal in two forms of hereditary androgen resistance in addition to complete testicular feminization suggests either that these disorders are the result of allelic mutations affecting the function of the androgen-binding protein or that normal dihydrotestosterone binding requires the participation of more than one gene product.
INTRODUCTION
Hereditary male pseudohermaphroditism in which genetic men differentiate partly or completely as females can result from abnormalities in either of the two primary processes required for the masculinization of the male embryo, namely, mullerian duct regression or androgen-mediated virilization of the wolffian ducts, urogenital sinus, and external genitalia (1, 2) . The defects in the androgen-mediated sequence can be further divided into at least two categories, namely, genetic defects in testosterone formation and abnormalities in an-in which androgen production is normal and in which the entire syndrome is presumed to be the result of resistance to androgen action, namely, the complete and incomplete forms of testicular feminization and familial incomplete male pseudohermaphroditism, types 1 and 2 (1, 2) .
In two of the disorders, the molecular basis of the mutation has been the subject of considerable study. For example, evidence suggests that the autosomal recessive disorder familial incomplete male pseudohermaphroditism, type 2 (pseudovaginal perineoscrotal hypospadias) may be due to a defect in the 5a-reductase enzyme that converts testosterone' to dihydrotestosterone in the accessory organs of male reproduction. As a result, the urogenital sinus and external genitalia of affected males differentiate in a predominantly female fashion, but virilization of the wolffian ducts, which is mediated by testosterone itself, is normal (3-6). Furthermore, in cultured fibroblasts from subjects with the complete form of testicular feminization there is a deficiency of the binding protein that is presumed to be essential to the intracellular action of androgens (7) (8) (9) . As a result, all androgen-mediated processes are deficient in this disease, and development of the wolffian duct as well as the urogenital sinus and urogenital tubercle is female in character.
Nothing is known about the pathogenesis of the androgen resistance in the other disorders of androgen action. overnight at 4'C with 10 mg Norit A per ml serum. The mixture was centrifuged, the charcoal treatment was repeated twice, and the serum was then passed through 0.45-,um Millipore filters. Testosterone was measured on treated and untreated serum by the method of Milewich et al. (11) , and estrogens were measured by the procedure of Mikhail et al. (12) . The untreated serum contained 0.27 ng/ml testosterone, 335 pg/ml estradiol, and 27 pg/ml estrone, and after charcoal treatment, the respective values were < 0.08 ng/ml, < 20 pg/ml, and < 20 pg/ml.
Cell culture. The fibroblast strains used in these experiments were established from explants of genital and nongenital skin from a variety of control subjects and from patients with different forms of male pseudohermaphroditism after obtaining informed written consent from the patients or from their parents (Table I ). In the case of the control subjects, the skin samples were taken from skin removed at the time of circumcision or at the time of surgery for unrelated problems. Skin samples from the patients with male pseudohermaphroditism were obtained at the time of surgery or from punch biopsy under local anesthesia.
The patient designated "incomplete testicular feminization" (strain 156) has been reported in detail (13 Density gradient binding. For the density gradient studies 5 X 106 cells were seeded into roller bottles with a surface area of 690 cm2 and containing 100 ml medium A. The bottles were gassed with 5%o C02 in air, capped, and incubated at 370C on a Bellco cell production roller apparatus (0.4 rpm for 24 h and 0.6 rpm thereafter). On days 3 and 6 the medium was replaced with 100 ml medium B. On day 7 the roller bottles were rinsed twice with 15 ml medium C.
50 ml of 1 nM [3H]dihydrotestosterone in medium C with or without additional nonradioactive dihydrotestosterone were added to each, and the bottles were incubated for 45 min at 37°C. The medium was removed, and the cells were harvested by scraping with a rubber policeman. Cell suspensions were kept at 0C. Cell suspensions were centrifuged at 1,500 rpm (480 g) for 2 min, and the pellets were resuspended in 2 ml of 0.9%o NaCl. After a second centrifugation for 2 min at 1,500 rpm the pellets were resuspended in an equal vol of 20 mM Tris, 1.5 mM EDTA, pH 7.4, containing Trasylol, 5,000 U/ml, with or without 0.5 M KCl. Cell suspensions were then submitted to sonic disruption using a Biosonik III ultrasonic system (Will Scientific, Inc., Rochester, N. Y.) at 50 W power with two 5-s periods of sonication with a needle probe (5 X A inch). Sonicates were centrifuged 1 h at 100,000 g, and the supernate was separated. An aliquot was removed for protein determination, and 200 ul of supernate were layered on the top of 5.3 ml of a 5-20% sucrose gradient containing 10% glycerol in 20 mM Tris chloride and 1.5 mM EDTA, pH 7.4, with or without 0.5 M KCl. Osmolarity of the cytosol was measured with a 5100 vapor pressure osmometer (Wescor Inc., Logan, Utah). For some experiments the 100,000-g pellet was reextracted with the Tris-EDTA buffer containing 0.5 M KCl, sonicated once for 5 s, and centrifuged at 100,000 g for 1 h. Density gradients were centrifuged for 18 h in a SW 50.1 rotor at 50,000 rpm (250,000 g) at 0C in a Beckman L5 ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). 5-drop fractions were collected from the bottom of the gradient and assayed for radioactivity in 4.5 ml of 0.4% 2,4-diphenyloxazole in xyleneTriton X-114 (3 were dissolved in 20 pAI chloroform containing 5 jsg each of five nonradioactive steroids (androstanedione, androstenedione, dihydrotestosterone, testosterone, and androstanediol) and applied to 20 X 20-cm precoated plastic sheets of silica gel without gypsum. The plates were developed with one ascent of the solvent system dichloromethane: ethyl acetate: methanol (85: 15: 3, vol/vol/vol), air-dried, sprayed with anisaldehyde reagent (100 ml glacial acetic acid, 2 ml of concentrated H2SO4, 1 ml of p-anisaldehyde), and heated at 100°C for 15 min. Within each lane the zones corresponding to the five reference steroids were marked, cut with scissors, and assayed for 3H in 10 ml 0.4% 2,4-diphenyloxazole in toluene-methanol (10: 1, vol/vol).
RESULTS
When normal human fibroblasts were incubated with 0.2 nM [5H]dihydrotestosterone, the cellular radioactivity increased rapidly for 15 min and then approached a plateau (Fig. 1) . The initial rate of uptake and the height of the apparent plateau were greater as the temperature was increased from 4 to 37°C. At this concentration of [3H] dihydrotestosterone, uptake is due principally to specific high affinity binding (see Fig. 2 dihydrotestosterone (60 fmol/mg protein with a half maximum saturation of 0.1 nM) and a low affinity component that did not saturate up to 5 nM and was not displaced by excess radioactive steroid ( Fig. 2A) . The high affinity uptake illustrated in Fig. 2A (Table II) . At the end of the 45 min incubation most of the intracellular radioactivity was recovered as unchanged dihydrotestosterone (Table  III) . With this assay high affinity binding was easily demonstrable in normal cell lines but was low in fibroblasts derived from labia majora and scrotum of patients with testicular feminization (Fig. 2B ) and with familial incomplete male pseudohermaphroditism, type 1 (Fig. 2C) . To characterize the uptake further, fibroblasts from a normal subject were exposed to [2H]dihydrotestosterone, washed, disrupted by ultrasound, and centrifuged at 100,000 g, and the supernate was subjected to density gradient centrifugation in 5-20% sucrose (Fig. 3) . In preliminary experiments binding in the 8S region was demonstrable only in homogenates containing about 10 mg protein/ml (results not shown), and all subsequent extracts were made in 1. 1 (vol: vol) homogenates with incubation conditions similar to those for the monolayer assay, i.e., 1 nM [1,2,4,5,6,7-3H]dihydrotestosterone at 370C for 45 min. In experiments in which the supernate was extracted after an additional 18-h incubation at 40C, 98% of the radioactivity was recovered as unchanged dihydrotestosterone, indicating that the supernatant radioactivity did in fact represent dihydrotestosterone. When extracts of fibroblasts from normal labia majora were prepared in low ionic strength buffer that resulted in a final osmolality of 282 mosM, the major radioactivity was in a peak of approximate 8S, and a smaller peak of approximate 4S was also identified.
When the 100,000-g pellet remaining from this preparation was reextracted in 0.5 M KCl and again centrifuged, radioactivity was recovered in the 4S but not in the 8S region. When an aliquot of the cells was extracted initially in 0.5 M KCI the only radioactive peak was in the 4S region (Fig. 3) (Fig. 4) . Since more than 90% of the radioactivity in the supernate in these experiments was re-1346 J. E. Griffin, K. Punyashthiti, and J. D. Wilson covered bound to a macromolecule and was displaced by excess nonradioactive steroid, it was concluded that the high affinity component of the uptake of ['H]dihydrotestosterone by intact monolayers did in fact represent binding.
The monolayer assay was then used for a comparative study of dihydrotestosterone binding by fibroblasts from normal subjects and from patients with disorders of sexual differentiation. The intercept of the specific binding curve on the ordinate in femtomoles per milligram protein (as illustrated in Fig. 2 ) has been plotted in Fig. 5 for measurements in 31 fibroblast strains derived from 5 patients with complete testicular feminization, 3 patients with familial incomplete male pseudohermaphroditism, type 1, 2 patients with familial incomplete male pseudohermaphroditism, type 2, 1 patient each with incomplete testicular feminization and 17p-hydroxysteroid dehydrogenase deficiency, and 14 control subjects. The control fibroblasts include cells derived from genital skin (scrotum, labia majora, and foreskin) and from nongenital skin and includes subjects with developmental defects of the genital tract (hypospadias and cryptorchidism) as well as individuals with no known disease of the urogenital system. For purposes of this analysis labia majora and scrotum have been charted together because of their common embryological derivation. In 25 separate determinations of dihydrotestosterone binding in 9 control fibroblast strains of labia majora and scrotum, the values ranged After sonic disruption the extracts were centrifuged at 100,000 g for 1 h, and the supernate was decanted. The 100,000-g pellet from the low ionic strength sample was reextracted with Tris-EDTA-Trasylol containing 0.5 M KCI, sonicated, and recentrifuged at 100,000 g for 1 h.
200-,td samples of the various supernates (containing 10 mg protein/ml for the low ionic strength extract, 4.2 mg protein/ml for the KCl-extracted pellet, and 11.9 mg protein/ ml for the sample extracted initially with KCl) were applied to 5-20% sucrose gradients containing 10% glycerol, 20 mM Tris, and 1.5 mM EDTA, pH 7.4, with or without added 0.5 M KCl. The tubes were centrifuged for 18 h at 50,000 rpm, and 5-drop fractions were collected and assayed for radioactivity. The arrow represents the position of [14C] albumin, the internal marker for the gradient. Fraction 1 represents the bottom of the gradient. from 20 to 75 fmol/mg protein. On an average, there was more high affinity binding in the fibroblasts derived from genital skin (44, 36, and 28 fmol/mg protein in foreskin, labia majora, and scrotum, respectively) than for fibroblasts derived from nongenital skin (14 fmol/ mg protein). Furthermore, in three instances binding was compared in fibroblasts grown from genital and nongenital skin of the same individual, and in each specific binding was greater in the fibroblasts grown from genital skin (Table IV) . The approximate half maximum concentrations for high affinity binding were similar in all control fibroblasts (approximately 0.1-0.2 nM). Binding was normal in the genital and nongenital cells from two patients with familial incomplete male pseudo- hermaphroditism, type 2 and in the nongenital fibroblasts from the patient with 171-hydroxysteroid dehydrogenase deficiency.
As expected, binding was almost undetectable in four fibroblast strains derived from labia majora and in one fibroblast strain from deltoid skin of patients with complete testicular feminization. In the fibroblasts from the The number of high affinity binding sites was determined as in Fig. 2 . and the intercept of the specific binding curve with the ordinate has been termed "high affinity dihydrotestosterone binding." patient with incomplete testicular feminization, binding in four separate experiments averaged 14 (range 9-18) fmol/mg protein, a value between the average for complete testicular feminization (4 fmol/mg protein) and that for normal labia majora (36 fmol/mg protein). Binding in the three fibroblast strains from subjects with familial male pseudohermaphroditism, type 1 ranged from a level indistinguishable from that of complete testicular feminization in one case (6 fmol/mg protein in strain 158) to values approaching that in incomplete testicular feminization in the others (an average of 13 and 11 fmol/mg protein in strains 327 and 333, respectively).
Representative experiments from a comparative study of dihydrotestosterone binding by density gradient centrifugation are illustrated in Fig. 6 . In fibroblasts from genital skin of normal subjects binding was demonstrable in the 8S region of the low ionic strength extracts and the 4S region of KCl extracts of the pellets (Fig. 6A-6C ). Normal binding in the 8S and 4S regions was also demonstrated in fibroblasts from both the nongenital skin (strain 136) and foreskin (strain 139) of a patient with familial incomplete male pseudohermaphroditism, type 2 (results not shown). In a comparable preparation from the fibroblasts of a patient with complete testicular feminization virtually no binding was demonstrable in either high or low ionic strength buffers (Fig. 6D) . Similar (Fig. 6E ). In the low and high molarity extracts of scrotal fibroblasts from the patient with the type 1 form of familial incomplete male pseudohermaphroditism, binding was almost immeasurable and again could not be distinguished from that seen in the complete form of testicular feminization (Fig. 6F) . FIGURE 5 Specific binding of [1, 2, 4, 5, 6, 7] in fibroblasts grown from genital skin than from nongenital sites, and that the high affinity binding is absent in fibroblasts from patients with complete testicular feminization is a confirmation of the previous findings of Keenan and his co-workers (7, 8) . In addition, several new aspects of this process have been studied.
First, the size of the binding protein was investigated as a function of the molarity of the homogenates. In isotonic homogenates of normal cells dihydrotestosterone binding is principally in the 8S region of the gradient, whereas in high molarity buffers the major binding peak is in the 4-4.5S region. Thus, the cultured human fibroblast has an approximate 8S dihydrotestosterone-binding protein similar to the one characterized in other androgen target tissues such as rat prostate (16, 17) , rat preputial gland (18) , mouse kidney (19) (20) (21) , and mouse submandibular gland (22) .
Second, the assessment of dihydrotestosterone binding both by the monolayer assay and by density gradient centrifugation has been made in the fibroblasts from five different types of hereditary male pseudohermaphroditism in addition to complete testicular feminization. In fibroblasts from patients with complete testicular feminization high affinity binding and the 8S and 4S peaks were virtually absent. These results agree with the findings of Keenan et al. (7, 8) . Since this syndrome is believed to be the result of complete resistance to androgen action both during embryogenesis and in the postnatal state as well, the absence of the binding that is believed to be essential for the movement of dihydrotestosterone into the nucleus of the cell provides a likely explanation of the pathogenesis of the androgen resistance and the male pseudohermaphroditism as well.
In fibroblasts derived from the foreskin of two patients with familial incomplete male pseudohermaphroditism, type 2, high affinity binding was in the normal range. This finding is in keeping with the concept that the fundamental defect in this disorder is deficient dihydrotestosterone formation in androgen-target tissues (3) (4) (5) (6) and indicates that dihydrotestosterone itself does not regulate its binding protein. Dihydrotestosterone binding was also normal in fibroblasts from the arm skin of a patient with 17#-hydroxysteroid dehydrogenase deficiency in which the male pseudohermaphroditism is the result of defective testosterone synthesis during embryogenesis (23, 24) . The normal values in these types of male pseudohermaphroditism, plus the normal values in fibroblasts from a subject with hypospadias and a patient with bilateral cryptorchidism, indicate that dihydrotestosterone binding is not influenced by malformations of the genital tract per se.
The results in familial incomplete male pseudohermaphroditism, type 1 are of particular interest. Like testicular feminization, this disorder is presumed to be due to a X-linked mutation, and the evidence is clear-cut in both disorders that the androgen resistance cannot be due to deficient formation of dihydrotestosterone (3, 4) . Unlike testicular feminization, however, there is extreme variability in the expression of the mutant gene in that affected individuals within the same pedigree can range from almost normal males to extreme degrees of male pseudohermaphroditism (14, 25) . The fact that dihydrotestosterone binding in scrotal fibroblasts from three affected individuals from one pedigree was low suggests that the androgen resistance in this disorder can also be explained as the result of abnormal dihydrotestosterone binding. Whether this mutation is allelic to that of testicular feminization or whether it involves some separate gene that regulates the binding protein is not clear.
The results in the case of incomplete testicular feminization are also of interest. The nature of the underlying mutation in this disorder is not clear in that familial occurrence has not been documented. As used here, the term describes a distinct phenotype distinguishable from testicular feminization only in that there is some evidence of androgenization of the internal and external genitalia at birth and in that partial virilization as well as feminization takes place at the time of puberty (13) . The fact that both by the monolayer assay and density gradient centrifugation dihydrotestosterone binding is lower than normal suggests that androgen resistance in this disease may also result from defective dihydrotestosterone binding.
To determine whether the defects in these two forms of partial male pseudohermaphroditism are due to abnormalities in the amount of the dihydrotestosteronebinding protein or to a mutant protein that does not bind dihydrotestosterone normally, it will be necessary to develop more sensitive assays of dihydrotestosterone binding. On the basis of the evidence at hand it seems reasonable to conclude that the finding of low amounts of high affinity dihydrotestosterone binding by present methods is not diagnostic of complete testicular feminization but may be characteristic of other types of hereditary androgen resistance as well. Furthermore, the fact that dihydrotestosterone binding is abnormal in several forms of hereditary androgen resistance suggests either that these disorders are the result of allelic mutations affecting the function of the androgen-binding protein or that normal dihydrotestosterone binding requires the participation of more than one gene product.
